Matt Henriksen

Rich and Jared, thank you both for joining us today.

Glad to be here.

Thank you.

Thanks, Matt.

And why don't we just start with both of your career paths?

Jared, I might start with you first, because as a co-founder, you took the steps to see an unmet need in really a market that seems to be innovating very, very quickly.

So just curious your thoughts of how you came about founding this company.

Rich, you joined a little bit later, but your career was very well established in the diabetes space beforehand.

Why don't you let the listeners know your career path that got you to BioLink?

Yeah.

And I mean, we will jump into the technology in a few minutes, but this is an interesting episode for me personally, because we're talking about, usually in these episodes, I talk about an antiquated technology that's being disrupted by new innovation.

This episode has the potential to talk about a gold standard that has disrupted a previous standard of care with new technology.

And so I think we just need to take a step back and walk through how CGMs disrupted the glucose monitor market in the first place over those 20 years and what you saw expand and how that technology expanded over those two decades.

Well, and 20 years ago, why was it so hard to be able to get that continuous readings of the glucose levels?

Because, you know, I'm thinking like the antiquated way is, you know, you prick your finger four times a day.

Right.

And so basically get four readings a day.

Now you're doing, if I did my math right, you know, five minutes between readings, that's 288 readings without pricking your finger.

So what was the technology to get?

to those 288 readings accurately.